This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter: revenue up 31.9%, profit after tax up 168.3%
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unaudited consolidated results for the quarter ended 30 September 2026 show revenue of Rs 1,342.39 crore, up 31.9% from Rs 1,017.53 crore a year earlier, and profit after tax of Rs 114.57 crore, up 168.3% from Rs 42.70 crore. Operating profit before interest, tax, depreciation and amortisation margin rose to 14.5% from 9.3%. The auditor review was unmodified but highlighted an appealed Rs 156.02 crore tax demand for the group.
Strong revenue, profit and margin growth is positive for sentiment, but the appealed Rs 156.02 crore tax demand remains a material risk.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹1,342 Cr | ₹1,018 Cr | +31.9% |
| Operating profit | ₹125.8 Cr | ₹33.31 Cr | +277.8% |
| Profit after tax | ₹114.6 Cr | ₹42.70 Cr | +168.3% |
| EBITDA margin | 14.5% | 9.3% | +5.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.